Global Metabolomics

Metabolomics Comprehensive Study by Application (Drug Assessment, Biomarker Discovery, Nutrigenomics, Clinical toxicology, Others), Indication (Cancer, Cardiovascular Disorders, Neurological Disorders, Inborn Errors of Metabolism, Other Indications), Technique (Separation Techniques {Gas Chromatography (GC), Capillary Electrophoresis (CE)‏, High Performance Liquid Chromatography (HPLC)‏, Ultra Performance Liquid Chromatography (UPLC)‏, Detection Techniques {Nuclear Magnetic Resonance Spectroscopy (NMR)‏, Mass Spectrometry (MS)}) Players and Region - Global Market Outlook to 2028

Metabolomics Market by XX Submarkets | Forecast Years 2023-2028 | CAGR: 13.9%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Metabolomics is the extensive study of small molecules, generally known as metabolites, within cells, biofluids, organisms or tissues. Comprehensively, these small molecules and their interactions in the biological system are known as the metabolome. It is a powerful approach as metabolites and their concentrations, unlike other omics measures, directly reflect the underlying biochemical activity and state of tissues/cells. Therefore, metabolomics best represents the molecular phenotype.

Highlights from Metabolomics Market Study
AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Value (2028)USD 3565.82 Million
UnitValue (USD Million)
CAGR13.9%


The key Players profiled in the report are Agilent Technologies, Inc. (United States), Danaher Corporation (United States), Biocrates Life Sciences AG (Austria), Bruker Corporation (United States), Leco Corporation (United States), Metabolon, Inc. (United States), Human Metabolome Technologies, Inc. (Japan), Bio-Rad Laboratories, Inc. (United States), Shimadzu Corporation (Japan), Waters Corporation (United States) and Thermo Fisher Scientific Inc. (United States).

Geographic Breakdown and Segment Analysis
The Global Metabolomics market presents a comprehensive analysis of the Metabolomics market by end-user/application (Drug Assessment, Biomarker Discovery, Nutrigenomics, Clinical toxicology and Others), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. This section of our report presents a realistic picture of the Global Metabolomics industry. Investors and Players can easily understand the inherent opportunities and challenges for their products in the geographical region of interest. For instance, while the holds majority of market share of the Metabolomics market

Analyst at AMA have segmented the market study of Global Metabolomics market by Type, Application and Region.

Metabolomics Market Dynamics:
AttributesDetails
Growth Drivers
  • Growth in Demand for Personalized Medicines
  • The upsurge in R&D Investment for Development of Metabolomics
  • The rise in Global Incidences of Chronic Diseases
  • Technological Advancements in Analytical Techniques
Restraints
  • High Cost of Metabolic Instruments
  • Lack of Skilled Professionals
Gaps & Opportunities
  • Immense Potential in Disease Diagnostics
  • Emerging Prospect in Human Nutrition


Market Developments Activities:
On 5 Sept. 2017, Metabolon, Inc., the global leader in metabolomics, has announced the acquisition of Metabolomic Discoveries GmbH, a leading metabolomics services and diagnostics company based near Berlin, Germany. In addition to the acquisition of Metabolomic Discoveries, Metabolon has also established joint laboratory collaborations with organizations in China and the Middle East.
On 23 Oct 2017, ThermoFisher, Updated with new capabilities in high-resolution accurate mass (HRAM) GC-MS, the Thermo Scientific Orbitrap GC-MS systems now give users across metabolomics, environmental, food safety, pharma & toxicology applications high levels of accuracy in their data.





Key Target Audience
Metabolomics Companies, Research Firms, Regulatory Bodies, Government Bodies, Downstream Vendors and Others

Report Objectives / Segmentation Covered

By Application
  • Drug Assessment
  • Biomarker Discovery
  • Nutrigenomics
  • Clinical toxicology
  • Others
By Indication
  • Cancer
  • Cardiovascular Disorders
  • Neurological Disorders
  • Inborn Errors of Metabolism
  • Other Indications

By Technique
  • Separation Techniques {Gas Chromatography (GC), Capillary Electrophoresis (CE)‏, High Performance Liquid Chromatography (HPLC)‏, Ultra Performance Liquid Chromatography (UPLC)‏
  • Detection Techniques {Nuclear Magnetic Resonance Spectroscopy (NMR)‏, Mass Spectrometry (MS)}

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growth in Demand for Personalized Medicines
      • 3.2.2. The upsurge in R&D Investment for Development of Metabolomics
      • 3.2.3. The rise in Global Incidences of Chronic Diseases
      • 3.2.4. Technological Advancements in Analytical Techniques
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Metabolomics, by Application, Indication, Technique and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Metabolomics (Value)
      • 5.2.1. Global Metabolomics by: Application (Value)
        • 5.2.1.1. Drug Assessment
        • 5.2.1.2. Biomarker Discovery
        • 5.2.1.3. Nutrigenomics
        • 5.2.1.4. Clinical toxicology
        • 5.2.1.5. Others
      • 5.2.2. Global Metabolomics by: Indication (Value)
        • 5.2.2.1. Cancer
        • 5.2.2.2. Cardiovascular Disorders
        • 5.2.2.3. Neurological Disorders
        • 5.2.2.4. Inborn Errors of Metabolism
        • 5.2.2.5. Other Indications
      • 5.2.3. Global Metabolomics by: Technique (Value)
        • 5.2.3.1. Separation Techniques {Gas Chromatography (GC), Capillary Electrophoresis (CE)‏, High Performance Liquid Chromatography (HPLC)‏, Ultra Performance Liquid Chromatography (UPLC)‏
        • 5.2.3.2. Detection Techniques {Nuclear Magnetic Resonance Spectroscopy (NMR)‏, Mass Spectrometry (MS)}
      • 5.2.4. Global Metabolomics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Metabolomics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Agilent Technologies, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Danaher Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Biocrates Life Sciences AG (Austria)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bruker Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Leco Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Metabolon, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Human Metabolome Technologies, Inc. (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bio-Rad Laboratories, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Shimadzu Corporation (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Waters Corporation (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Thermo Fisher Scientific Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Metabolomics Sale, by Application, Indication, Technique and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Metabolomics (Value)
      • 7.2.1. Global Metabolomics by: Application (Value)
        • 7.2.1.1. Drug Assessment
        • 7.2.1.2. Biomarker Discovery
        • 7.2.1.3. Nutrigenomics
        • 7.2.1.4. Clinical toxicology
        • 7.2.1.5. Others
      • 7.2.2. Global Metabolomics by: Indication (Value)
        • 7.2.2.1. Cancer
        • 7.2.2.2. Cardiovascular Disorders
        • 7.2.2.3. Neurological Disorders
        • 7.2.2.4. Inborn Errors of Metabolism
        • 7.2.2.5. Other Indications
      • 7.2.3. Global Metabolomics by: Technique (Value)
        • 7.2.3.1. Separation Techniques {Gas Chromatography (GC), Capillary Electrophoresis (CE)‏, High Performance Liquid Chromatography (HPLC)‏, Ultra Performance Liquid Chromatography (UPLC)‏
        • 7.2.3.2. Detection Techniques {Nuclear Magnetic Resonance Spectroscopy (NMR)‏, Mass Spectrometry (MS)}
      • 7.2.4. Global Metabolomics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Metabolomics: by Application(USD Million)
  • Table 2. Metabolomics Drug Assessment , by Region USD Million (2017-2022)
  • Table 3. Metabolomics Biomarker Discovery , by Region USD Million (2017-2022)
  • Table 4. Metabolomics Nutrigenomics , by Region USD Million (2017-2022)
  • Table 5. Metabolomics Clinical toxicology , by Region USD Million (2017-2022)
  • Table 6. Metabolomics Others , by Region USD Million (2017-2022)
  • Table 7. Metabolomics: by Indication(USD Million)
  • Table 8. Metabolomics Cancer , by Region USD Million (2017-2022)
  • Table 9. Metabolomics Cardiovascular Disorders , by Region USD Million (2017-2022)
  • Table 10. Metabolomics Neurological Disorders , by Region USD Million (2017-2022)
  • Table 11. Metabolomics Inborn Errors of Metabolism , by Region USD Million (2017-2022)
  • Table 12. Metabolomics Other Indications , by Region USD Million (2017-2022)
  • Table 13. Metabolomics: by Technique(USD Million)
  • Table 14. Metabolomics Separation Techniques {Gas Chromatography (GC), Capillary Electrophoresis (CE)‏, High Performance Liquid Chromatography (HPLC)‏, Ultra Performance Liquid Chromatography (UPLC)‏ , by Region USD Million (2017-2022)
  • Table 15. Metabolomics Detection Techniques {Nuclear Magnetic Resonance Spectroscopy (NMR)‏, Mass Spectrometry (MS)} , by Region USD Million (2017-2022)
  • Table 16. South America Metabolomics, by Country USD Million (2017-2022)
  • Table 17. South America Metabolomics, by Application USD Million (2017-2022)
  • Table 18. South America Metabolomics, by Indication USD Million (2017-2022)
  • Table 19. South America Metabolomics, by Technique USD Million (2017-2022)
  • Table 20. Brazil Metabolomics, by Application USD Million (2017-2022)
  • Table 21. Brazil Metabolomics, by Indication USD Million (2017-2022)
  • Table 22. Brazil Metabolomics, by Technique USD Million (2017-2022)
  • Table 23. Argentina Metabolomics, by Application USD Million (2017-2022)
  • Table 24. Argentina Metabolomics, by Indication USD Million (2017-2022)
  • Table 25. Argentina Metabolomics, by Technique USD Million (2017-2022)
  • Table 26. Rest of South America Metabolomics, by Application USD Million (2017-2022)
  • Table 27. Rest of South America Metabolomics, by Indication USD Million (2017-2022)
  • Table 28. Rest of South America Metabolomics, by Technique USD Million (2017-2022)
  • Table 29. Asia Pacific Metabolomics, by Country USD Million (2017-2022)
  • Table 30. Asia Pacific Metabolomics, by Application USD Million (2017-2022)
  • Table 31. Asia Pacific Metabolomics, by Indication USD Million (2017-2022)
  • Table 32. Asia Pacific Metabolomics, by Technique USD Million (2017-2022)
  • Table 33. China Metabolomics, by Application USD Million (2017-2022)
  • Table 34. China Metabolomics, by Indication USD Million (2017-2022)
  • Table 35. China Metabolomics, by Technique USD Million (2017-2022)
  • Table 36. Japan Metabolomics, by Application USD Million (2017-2022)
  • Table 37. Japan Metabolomics, by Indication USD Million (2017-2022)
  • Table 38. Japan Metabolomics, by Technique USD Million (2017-2022)
  • Table 39. India Metabolomics, by Application USD Million (2017-2022)
  • Table 40. India Metabolomics, by Indication USD Million (2017-2022)
  • Table 41. India Metabolomics, by Technique USD Million (2017-2022)
  • Table 42. South Korea Metabolomics, by Application USD Million (2017-2022)
  • Table 43. South Korea Metabolomics, by Indication USD Million (2017-2022)
  • Table 44. South Korea Metabolomics, by Technique USD Million (2017-2022)
  • Table 45. Taiwan Metabolomics, by Application USD Million (2017-2022)
  • Table 46. Taiwan Metabolomics, by Indication USD Million (2017-2022)
  • Table 47. Taiwan Metabolomics, by Technique USD Million (2017-2022)
  • Table 48. Australia Metabolomics, by Application USD Million (2017-2022)
  • Table 49. Australia Metabolomics, by Indication USD Million (2017-2022)
  • Table 50. Australia Metabolomics, by Technique USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Metabolomics, by Application USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Metabolomics, by Indication USD Million (2017-2022)
  • Table 53. Rest of Asia-Pacific Metabolomics, by Technique USD Million (2017-2022)
  • Table 54. Europe Metabolomics, by Country USD Million (2017-2022)
  • Table 55. Europe Metabolomics, by Application USD Million (2017-2022)
  • Table 56. Europe Metabolomics, by Indication USD Million (2017-2022)
  • Table 57. Europe Metabolomics, by Technique USD Million (2017-2022)
  • Table 58. Germany Metabolomics, by Application USD Million (2017-2022)
  • Table 59. Germany Metabolomics, by Indication USD Million (2017-2022)
  • Table 60. Germany Metabolomics, by Technique USD Million (2017-2022)
  • Table 61. France Metabolomics, by Application USD Million (2017-2022)
  • Table 62. France Metabolomics, by Indication USD Million (2017-2022)
  • Table 63. France Metabolomics, by Technique USD Million (2017-2022)
  • Table 64. Italy Metabolomics, by Application USD Million (2017-2022)
  • Table 65. Italy Metabolomics, by Indication USD Million (2017-2022)
  • Table 66. Italy Metabolomics, by Technique USD Million (2017-2022)
  • Table 67. United Kingdom Metabolomics, by Application USD Million (2017-2022)
  • Table 68. United Kingdom Metabolomics, by Indication USD Million (2017-2022)
  • Table 69. United Kingdom Metabolomics, by Technique USD Million (2017-2022)
  • Table 70. Netherlands Metabolomics, by Application USD Million (2017-2022)
  • Table 71. Netherlands Metabolomics, by Indication USD Million (2017-2022)
  • Table 72. Netherlands Metabolomics, by Technique USD Million (2017-2022)
  • Table 73. Rest of Europe Metabolomics, by Application USD Million (2017-2022)
  • Table 74. Rest of Europe Metabolomics, by Indication USD Million (2017-2022)
  • Table 75. Rest of Europe Metabolomics, by Technique USD Million (2017-2022)
  • Table 76. MEA Metabolomics, by Country USD Million (2017-2022)
  • Table 77. MEA Metabolomics, by Application USD Million (2017-2022)
  • Table 78. MEA Metabolomics, by Indication USD Million (2017-2022)
  • Table 79. MEA Metabolomics, by Technique USD Million (2017-2022)
  • Table 80. Middle East Metabolomics, by Application USD Million (2017-2022)
  • Table 81. Middle East Metabolomics, by Indication USD Million (2017-2022)
  • Table 82. Middle East Metabolomics, by Technique USD Million (2017-2022)
  • Table 83. Africa Metabolomics, by Application USD Million (2017-2022)
  • Table 84. Africa Metabolomics, by Indication USD Million (2017-2022)
  • Table 85. Africa Metabolomics, by Technique USD Million (2017-2022)
  • Table 86. North America Metabolomics, by Country USD Million (2017-2022)
  • Table 87. North America Metabolomics, by Application USD Million (2017-2022)
  • Table 88. North America Metabolomics, by Indication USD Million (2017-2022)
  • Table 89. North America Metabolomics, by Technique USD Million (2017-2022)
  • Table 90. United States Metabolomics, by Application USD Million (2017-2022)
  • Table 91. United States Metabolomics, by Indication USD Million (2017-2022)
  • Table 92. United States Metabolomics, by Technique USD Million (2017-2022)
  • Table 93. Canada Metabolomics, by Application USD Million (2017-2022)
  • Table 94. Canada Metabolomics, by Indication USD Million (2017-2022)
  • Table 95. Canada Metabolomics, by Technique USD Million (2017-2022)
  • Table 96. Mexico Metabolomics, by Application USD Million (2017-2022)
  • Table 97. Mexico Metabolomics, by Indication USD Million (2017-2022)
  • Table 98. Mexico Metabolomics, by Technique USD Million (2017-2022)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Metabolomics: by Application(USD Million)
  • Table 111. Metabolomics Drug Assessment , by Region USD Million (2023-2028)
  • Table 112. Metabolomics Biomarker Discovery , by Region USD Million (2023-2028)
  • Table 113. Metabolomics Nutrigenomics , by Region USD Million (2023-2028)
  • Table 114. Metabolomics Clinical toxicology , by Region USD Million (2023-2028)
  • Table 115. Metabolomics Others , by Region USD Million (2023-2028)
  • Table 116. Metabolomics: by Indication(USD Million)
  • Table 117. Metabolomics Cancer , by Region USD Million (2023-2028)
  • Table 118. Metabolomics Cardiovascular Disorders , by Region USD Million (2023-2028)
  • Table 119. Metabolomics Neurological Disorders , by Region USD Million (2023-2028)
  • Table 120. Metabolomics Inborn Errors of Metabolism , by Region USD Million (2023-2028)
  • Table 121. Metabolomics Other Indications , by Region USD Million (2023-2028)
  • Table 122. Metabolomics: by Technique(USD Million)
  • Table 123. Metabolomics Separation Techniques {Gas Chromatography (GC), Capillary Electrophoresis (CE)‏, High Performance Liquid Chromatography (HPLC)‏, Ultra Performance Liquid Chromatography (UPLC)‏ , by Region USD Million (2023-2028)
  • Table 124. Metabolomics Detection Techniques {Nuclear Magnetic Resonance Spectroscopy (NMR)‏, Mass Spectrometry (MS)} , by Region USD Million (2023-2028)
  • Table 125. South America Metabolomics, by Country USD Million (2023-2028)
  • Table 126. South America Metabolomics, by Application USD Million (2023-2028)
  • Table 127. South America Metabolomics, by Indication USD Million (2023-2028)
  • Table 128. South America Metabolomics, by Technique USD Million (2023-2028)
  • Table 129. Brazil Metabolomics, by Application USD Million (2023-2028)
  • Table 130. Brazil Metabolomics, by Indication USD Million (2023-2028)
  • Table 131. Brazil Metabolomics, by Technique USD Million (2023-2028)
  • Table 132. Argentina Metabolomics, by Application USD Million (2023-2028)
  • Table 133. Argentina Metabolomics, by Indication USD Million (2023-2028)
  • Table 134. Argentina Metabolomics, by Technique USD Million (2023-2028)
  • Table 135. Rest of South America Metabolomics, by Application USD Million (2023-2028)
  • Table 136. Rest of South America Metabolomics, by Indication USD Million (2023-2028)
  • Table 137. Rest of South America Metabolomics, by Technique USD Million (2023-2028)
  • Table 138. Asia Pacific Metabolomics, by Country USD Million (2023-2028)
  • Table 139. Asia Pacific Metabolomics, by Application USD Million (2023-2028)
  • Table 140. Asia Pacific Metabolomics, by Indication USD Million (2023-2028)
  • Table 141. Asia Pacific Metabolomics, by Technique USD Million (2023-2028)
  • Table 142. China Metabolomics, by Application USD Million (2023-2028)
  • Table 143. China Metabolomics, by Indication USD Million (2023-2028)
  • Table 144. China Metabolomics, by Technique USD Million (2023-2028)
  • Table 145. Japan Metabolomics, by Application USD Million (2023-2028)
  • Table 146. Japan Metabolomics, by Indication USD Million (2023-2028)
  • Table 147. Japan Metabolomics, by Technique USD Million (2023-2028)
  • Table 148. India Metabolomics, by Application USD Million (2023-2028)
  • Table 149. India Metabolomics, by Indication USD Million (2023-2028)
  • Table 150. India Metabolomics, by Technique USD Million (2023-2028)
  • Table 151. South Korea Metabolomics, by Application USD Million (2023-2028)
  • Table 152. South Korea Metabolomics, by Indication USD Million (2023-2028)
  • Table 153. South Korea Metabolomics, by Technique USD Million (2023-2028)
  • Table 154. Taiwan Metabolomics, by Application USD Million (2023-2028)
  • Table 155. Taiwan Metabolomics, by Indication USD Million (2023-2028)
  • Table 156. Taiwan Metabolomics, by Technique USD Million (2023-2028)
  • Table 157. Australia Metabolomics, by Application USD Million (2023-2028)
  • Table 158. Australia Metabolomics, by Indication USD Million (2023-2028)
  • Table 159. Australia Metabolomics, by Technique USD Million (2023-2028)
  • Table 160. Rest of Asia-Pacific Metabolomics, by Application USD Million (2023-2028)
  • Table 161. Rest of Asia-Pacific Metabolomics, by Indication USD Million (2023-2028)
  • Table 162. Rest of Asia-Pacific Metabolomics, by Technique USD Million (2023-2028)
  • Table 163. Europe Metabolomics, by Country USD Million (2023-2028)
  • Table 164. Europe Metabolomics, by Application USD Million (2023-2028)
  • Table 165. Europe Metabolomics, by Indication USD Million (2023-2028)
  • Table 166. Europe Metabolomics, by Technique USD Million (2023-2028)
  • Table 167. Germany Metabolomics, by Application USD Million (2023-2028)
  • Table 168. Germany Metabolomics, by Indication USD Million (2023-2028)
  • Table 169. Germany Metabolomics, by Technique USD Million (2023-2028)
  • Table 170. France Metabolomics, by Application USD Million (2023-2028)
  • Table 171. France Metabolomics, by Indication USD Million (2023-2028)
  • Table 172. France Metabolomics, by Technique USD Million (2023-2028)
  • Table 173. Italy Metabolomics, by Application USD Million (2023-2028)
  • Table 174. Italy Metabolomics, by Indication USD Million (2023-2028)
  • Table 175. Italy Metabolomics, by Technique USD Million (2023-2028)
  • Table 176. United Kingdom Metabolomics, by Application USD Million (2023-2028)
  • Table 177. United Kingdom Metabolomics, by Indication USD Million (2023-2028)
  • Table 178. United Kingdom Metabolomics, by Technique USD Million (2023-2028)
  • Table 179. Netherlands Metabolomics, by Application USD Million (2023-2028)
  • Table 180. Netherlands Metabolomics, by Indication USD Million (2023-2028)
  • Table 181. Netherlands Metabolomics, by Technique USD Million (2023-2028)
  • Table 182. Rest of Europe Metabolomics, by Application USD Million (2023-2028)
  • Table 183. Rest of Europe Metabolomics, by Indication USD Million (2023-2028)
  • Table 184. Rest of Europe Metabolomics, by Technique USD Million (2023-2028)
  • Table 185. MEA Metabolomics, by Country USD Million (2023-2028)
  • Table 186. MEA Metabolomics, by Application USD Million (2023-2028)
  • Table 187. MEA Metabolomics, by Indication USD Million (2023-2028)
  • Table 188. MEA Metabolomics, by Technique USD Million (2023-2028)
  • Table 189. Middle East Metabolomics, by Application USD Million (2023-2028)
  • Table 190. Middle East Metabolomics, by Indication USD Million (2023-2028)
  • Table 191. Middle East Metabolomics, by Technique USD Million (2023-2028)
  • Table 192. Africa Metabolomics, by Application USD Million (2023-2028)
  • Table 193. Africa Metabolomics, by Indication USD Million (2023-2028)
  • Table 194. Africa Metabolomics, by Technique USD Million (2023-2028)
  • Table 195. North America Metabolomics, by Country USD Million (2023-2028)
  • Table 196. North America Metabolomics, by Application USD Million (2023-2028)
  • Table 197. North America Metabolomics, by Indication USD Million (2023-2028)
  • Table 198. North America Metabolomics, by Technique USD Million (2023-2028)
  • Table 199. United States Metabolomics, by Application USD Million (2023-2028)
  • Table 200. United States Metabolomics, by Indication USD Million (2023-2028)
  • Table 201. United States Metabolomics, by Technique USD Million (2023-2028)
  • Table 202. Canada Metabolomics, by Application USD Million (2023-2028)
  • Table 203. Canada Metabolomics, by Indication USD Million (2023-2028)
  • Table 204. Canada Metabolomics, by Technique USD Million (2023-2028)
  • Table 205. Mexico Metabolomics, by Application USD Million (2023-2028)
  • Table 206. Mexico Metabolomics, by Indication USD Million (2023-2028)
  • Table 207. Mexico Metabolomics, by Technique USD Million (2023-2028)
  • Table 208. Research Programs/Design for This Report
  • Table 209. Key Data Information from Secondary Sources
  • Table 210. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Metabolomics: by Application USD Million (2017-2022)
  • Figure 5. Global Metabolomics: by Indication USD Million (2017-2022)
  • Figure 6. Global Metabolomics: by Technique USD Million (2017-2022)
  • Figure 7. South America Metabolomics Share (%), by Country
  • Figure 8. Asia Pacific Metabolomics Share (%), by Country
  • Figure 9. Europe Metabolomics Share (%), by Country
  • Figure 10. MEA Metabolomics Share (%), by Country
  • Figure 11. North America Metabolomics Share (%), by Country
  • Figure 12. Global Metabolomics share by Players 2022 (%)
  • Figure 13. Global Metabolomics share by Players (Top 3) 2022(%)
  • Figure 14. Global Metabolomics share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Agilent Technologies, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Agilent Technologies, Inc. (United States) Revenue: by Geography 2022
  • Figure 18. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 19. Danaher Corporation (United States) Revenue: by Geography 2022
  • Figure 20. Biocrates Life Sciences AG (Austria) Revenue, Net Income and Gross profit
  • Figure 21. Biocrates Life Sciences AG (Austria) Revenue: by Geography 2022
  • Figure 22. Bruker Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 23. Bruker Corporation (United States) Revenue: by Geography 2022
  • Figure 24. Leco Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 25. Leco Corporation (United States) Revenue: by Geography 2022
  • Figure 26. Metabolon, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Metabolon, Inc. (United States) Revenue: by Geography 2022
  • Figure 28. Human Metabolome Technologies, Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Human Metabolome Technologies, Inc. (Japan) Revenue: by Geography 2022
  • Figure 30. Bio-Rad Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Bio-Rad Laboratories, Inc. (United States) Revenue: by Geography 2022
  • Figure 32. Shimadzu Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 33. Shimadzu Corporation (Japan) Revenue: by Geography 2022
  • Figure 34. Waters Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 35. Waters Corporation (United States) Revenue: by Geography 2022
  • Figure 36. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2022
  • Figure 38. Global Metabolomics: by Application USD Million (2023-2028)
  • Figure 39. Global Metabolomics: by Indication USD Million (2023-2028)
  • Figure 40. Global Metabolomics: by Technique USD Million (2023-2028)
  • Figure 41. South America Metabolomics Share (%), by Country
  • Figure 42. Asia Pacific Metabolomics Share (%), by Country
  • Figure 43. Europe Metabolomics Share (%), by Country
  • Figure 44. MEA Metabolomics Share (%), by Country
  • Figure 45. North America Metabolomics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Agilent Technologies, Inc. (United States)
  • Danaher Corporation (United States)
  • Biocrates Life Sciences AG (Austria)
  • Bruker Corporation (United States)
  • Leco Corporation (United States)
  • Metabolon, Inc. (United States)
  • Human Metabolome Technologies, Inc. (Japan)
  • Bio-Rad Laboratories, Inc. (United States)
  • Shimadzu Corporation (Japan)
  • Waters Corporation (United States)
  • Thermo Fisher Scientific Inc. (United States)
Select User Access Type

Key Highlights of Report


Apr 2023 237 Pages 78 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Metabolomics Quantitative research analysis
Global Metabolomics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Due to pricing constraints we only profile limited players in the study that includes a mix list of leaders and emerging players, however for evaluation of market size the coverage includes 100+ players.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2028
The Study can be customized to meet your requirements. Please connect with our representative, in case you wish to add or remove certain country or profiled players.

Know More About Global Metabolomics Report?

Have a Query? Click Here

Other Related Reports

Microbiology Culture Comprehensive Study by Application (Metabolic Production, Biotransformation, Production of Biofuels, Treatment of Industrial Waste), End User Industry (Pharma Industry, Cosmetics...
$ 3750
Thermoplastic Rubber Comprehensive Study by Type (Thermoplastic Olefins, Vulcanized PP/EPDM Compound, Thermoplastic Polyurethane, Styrenic SBS, SEBS or SEPS Compound, Copolyester Compound, Thermoplas...
$ 3750
Cell Culture Media Comprehensive Study by Type (Chemically Defined Media, Serum Free Media, Protein Free Media, Classical Media, Custom Media, Lysogeny Broth), Application (Cell Research, Genetic Eng...
$ 3650
Hypericum Perforatum Extract Comprehensive Study by Type (Standard Product, Excellence Product), Application (Health Food, Medicine), End Users (Pharmaceuticals, Cosmetics, Food and Beverages, Govern...
$ 3750
Cell Culture Vessels Comprehensive Study by Type (Consumables, Reagents, Sera), Application (Biopharmaceutical Production (Therapeutic Proteins, Vaccine Production), Diagnostics, Drug Screening and D...
$ 3750
Radix Glycyrrhizae Comprehensive Study by Type (Paste Extract, Powder Extract, Dried Extract, Syrup Extract), Application (Pharmaceuticals, Food Industry, Tobacco, Others), End Use (Personal Use, Com...
$ 3500